
Keywords: Immunotherapy; allergy; asthma; omalizumab; allergens; recombinant; peptide; epicutaneous; intraepithelial; sublingual immunotherapy; AIT; Allergen immunotherapy; ILIT; Intralymphatic immunotherapy; MATA; Modified allergen tyrosine absorbate; MPL; Monopho